Mabwell Achieves Breakthrough Designation for Nectin-4 ADC Therapy with High Response Rates Mabwell announces a groundbreaking achievement with its Nectin-4 targeted ADC therapy, showing impressive response rates and receiving breakthrough designation.

Mabwell Achieves Breakthrough Designation for Nectin-4 ADC Therapy with High Response Rates #China #Shanghai #Mabwell #Nectin-4 #ADC_therapy